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Background: Extended spectrum β-lactamases (ESBLs) often associated with resistance to aminoglycosides and
fluoroquinolones have recently emerged in community-associated Escherichia coli. The worldwide clonal
dissemination of E. coli sequence type (ST)131 is playing a prominent role.
We describe an outbreak of colonizations by ESBL-producing E. coli (ESBL-E. coli) in the neonatal intensive care unit
(NICU) of the University Hospital, Palermo, Italy.
Methods: An epidemiological investigation was conducted with the support of molecular typing. All children
admitted to the NICU and colonized by ESBL-E. coli between January and June 2012, were included in the study.
Cases were defined as infants colonized by E. coli resistant to third generation cephalosporins and fluoroquinolones.
A case–control study was also performed to identify possible risk factors.
Results: During the outbreak period, 15 infants were found to be colonized by ESBL-E. coli. The epidemic strain
demonstrated continuous transmission throughout the outbreak period. Case–control study identified a lower birth
weight as the only risk factor for colonization. The strain belonged to the sequence-type 131 community-associated
clone. Transmission control interventions, including contact precautions and cohorting, restriction of the new
admissions, sanitization of surfaces and equipment and targeted training sessions of the NICU staff, were successful
in interrupting the outbreak.
Conclusions: Although invasive infections did not develop in any of the 15 colonized neonates, our report
highlights the need to strictly monitor the spill in the NICU setting of multidrug resistant community-associated
organisms. Our findings confirm also the role of active surveillance in detecting the silent spread of ESBL-producing
Gram negatives in a critical healthcare setting and trigging the implementation of infection control measures. As
β-lactam and fluoroquinolone resistant E. coli strains are increasingly spreading in the community, this event could
become a more serious challenge.
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Escherichia coli is a common cause of community and
healthcare associated infections. Over the past few decades,
E. coli strains isolated from community-acquired infections
have become increasingly resistant to antibacterial drugs
[1]. Recently, extended spectrum β-lactamases (ESBLs)
often associated with resistance to aminoglycosides and
fluoroquinolones have emerged in community-associated
E. coli [1,2]. The worldwide clonal dissemination of some
successful strains, such as E. coli sequence type (ST)131, is
playing a prominent role [1].
The identification of ESBL-producing E. coli (ESBL-
E.coli) as causative agents of infections in neonatal wards
is a worrying epidemiological development, because of the
serious limitations to inherently restricted therapeutic op-
tions. On the other hand, these healthcare settings are
proving to be particularly prone to the invasion by com-
munity associated multidrug resistant (MDR) organisms,
due to their peculiar position at the interface between hos-
pital and community [3-6].
We report here an outbreak of colonizations by an
ESBL-E.coli strain belonging to ST131 in the neonatal
intensive care unit (NICU) of the University Hospital in
Palermo, Italy.Methods
Epidemiological investigation
During the first semester of 2012, an unexpected increase
in the frequency of isolation of ESBL-E. coli was observed
in the NICU of the University Hospital “Azienda
Ospedaliero-Universitaria Policlinico P. Giaccone”, Palermo,
Italy. The NICU annually admits 250 infants approxi-
mately of all gestational ages (mean 36.7, range 26–42).
Because it is associated to the regional reference centre
for genetic diseases, the NICU has a high prevalence of
neonates with malformations (20% approximately) as well
as of outborn admissions (35% approximately). Moreover,
a further 20% proportion of patients has complex condi-
tions requiring subspecialty medical or surgical care. The
NICU includes one intensive care room consisting of 8
beds and one intermediate care room including 8 further
beds. The average nurse to patient ratio is 1:3 to 1:4 in the
two sections, respectively.
Since June 2009, a surveillance protocol is routinely in
place which includes rectal swabs obtained on a weekly
basis (every Tuesday) from all infants staying in the
NICU to monitor the prevalence of colonization with
multidrug resistant (MDR) Gram negatives.
All children admitted to the NICU and colonized by
ESBL-E. coli between January and June 2012, were in-
cluded in the study. Cases were defined as infants
colonized by E. coli simultaneously resistant to third gener-
ation cephalosporins and fluoroquinolones. Microbiologydatabase was queried as far back as January 2010 to iden-
tify additional ESBL-E. coli isolates.
The study protocol was approved by the Ethics Commit-
tee of the Azienda Ospedaliero-Universitaria Policlinico
“P. Giaccone”, Palermo, Italy, and informed consent was
sought in accordance with the principles of the Declar-
ation of Helsinki. Written informed consent was obtained
from the parents of each patient.
Case–control study
A case–control study was performed to look for possible
risk factors for the colonization by the ESBL-E.coli
strain. Controls were the infants who were being admit-
ted between the admission of the index case and the dis-
charge of the last case and had negative surveillance
cultures for ESBL-E.coli. For cases, risk factors were
assessed for the interval between admission and the first
positive culture for ESBL-E. coli. For controls, risk fac-
tors were assessed for the entire NICU stay. Data on
demographics, way of delivery, gestational age, birth
weight, singleton or twin pregnancy, antibiotics adminis-
tration, surgical procedures, exposure to devices and
length of stay were collected. Univariate analysis was
carried out by the EpiInfo software (ver.7; Centers for
Disease Control and Prevention, Atlanta, GA, US). Tests
of significance were performed with χ2 or Student’s t test
where appropriate. The assessment of certain risk factors
such as birth weight, length of stay, device exposures,
and length of antibiotic treatment, analysis of variance
(ANOVA) was used. Stepwise logistic regression analysis
of variables found significant in the univariate analysis
(P <0.10) was performed using StatPlus 2009 software.
All significance tests were two-tailed, and P <0.05 was
considered significant.
Microbiological investigations
Intestinal colonization by antibiotic-resistant Gram neg-
atives was assessed by culturing broth-enriched rectal
swabs onto MacConkey agar. Four antibiotic disks, con-
taining gentamicin (10 μg), amoxicillin-clavulanic acid
(20–10 μg), meropenem (10 μg) and ceftazidime (30 μg)
were placed on each plate before incubation. These anti-
microbial drugs were selected in order to include the two
more frequently used antibacterial drugs in UTIN, genta-
micin and amoxicillin-clavulanic acid, and two further anti-
biotics, such as ceftazidime and meropenem, that could
allow for timely detecting Gram negative organisms resist-
ant to cephalosporins and/or carbapenems. Selective media
were not employed, so that Gram negative colonization
could be detected and ceftazidime-susceptible and –non
susceptible organisms could be isolated. Colonies growing
into antibiotic inhibition halos were subcultured, biochem-
ically identified using API20E strips (Biomérieux, Marcy
l'Étoile, France) and submitted to antibiotic susceptibility
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detection were first performed by disk diffusion and
double disk synergy test and then confirmed by Etest
(Biomérieux, Marcy l'Étoile, France) methods according
with the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) guidelines [8]. An isolate
was defined as resistant to third generation cephalospo-
rins, when the inhibition zone diameter of ceftriaxone
(30 μg) and cefotaxime (5 μg) was < 20 mm and 17 mm,
respectively [8]. This isolate was defined as simultan-
eously resistant to fluoroquinolones when the inhibition
zone diameter of ciprofloxacin (5 μg) was < 19 mm [8].
E. coli ATCC 25922 was used as quality control strain.
An alert email was sent to NICU in the event of growth
of colonies or no inhibition zone around the ceftazidime
and/or meropenem disk.
E. coli phylogenetic group was determined by a triplex
polymerase chain reaction (PCR) assay as described pre-
viously [9].
Multiplex PCRs were used to amplify genes encoding
ESBLs [10]. blaCTX-M genes were amplified with specific
primers and sequenced. In addition, the aac(6’)-Ib-cr
aminoglycoside-quinolone resistance gene was character-
ized by PCR amplification and sequencing. Conjugation
experiments were performed using the E. coli strain K12J5
Rifr as a recipient. Plasmids were classified according toFigure 1 ESBL-producing Escherichia coli colonizations during the outtheir incompatibility group by using a PCR-based replicon
typing scheme [11].
Clonality of the ESBL-E. coli isolates was determined
by rep-PCR using the DiversiLab Escherichia kit for
DNA fingerprinting (BioMerieux, Marcy-l'Etoile, France)
[12]. E. coli isolates were further characterized by mul-
tilocus sequence typing (MLST) according to the Uni-
versity College Cork (Cork, Ireland) scheme for E. coli
(http://mlst.ucc.ie/mlst/dbs/Ecoli).
Results
Between February 7 and June 12, 2012, 15 infants were
found to be colonized by ESBL-E. coli (Figure 1). In this
interval of time, 103 newborns were admitted to the
NICU. Reviewing of the microbiology database showed
five ESBL-E.coli isolations in 2010 and two in 2011.
However, no clustering was evident.
The index case was a preterm infant with congenital
hydrocephalus born at 35 weeks gestational age, who
underwent surgical ventriculo-peritoneal derivation at
three days of life and antibiotic therapy with ampicillin-
sulbactam and gentamicin for the first 2 weeks of life.
Detection of ESBL-E. coli occurred after 18 days since
his admission to the NICU. Until March 27, 12 add-
itional cases of colonization were detected, two of whom
had been admitted before the index case (Table 1). Thebreak period.
Table 1 Characteristics of the infants colonized by ESBL-E. coli and risk factors at admission and during the NICU stay
Infant Date of
admission
Gestational age,
week / birth
weight, g.
Type of
delivery
Lengh of stay
(days)
Days in unit prior
to first positive
rectal swab
Feeding type Status at the
discharge time
1 December 27b 27/1140 CD 88 78 mixed alive
2 January 16 30/1110 CD 54 29 mixed alive
3a January 20 35/2420 CD 31 18 formula transferred to a
surgical ward
4 February 10 36/1970 CD 8 4 formula alive
5 February 16 30/720 CD 121 27 mixed alive
6 February 18 33/1910 CD 33 17 mixed alive
7 February 19 34/2270 VD 16 16 breast milk alive
8 February 22 38/2680 CD 16 13 formula alive
9 February 22 31/1790 VD 22 20 formula alive
10 February 23 37/1850 CD 12 12 mixed alive
11 February 27 38/u.i.c VD 11 8 formula alive
12 March 9 35/3300 CD 25 18 formula alive
13 March 19 40/3440 CD 3 1 formula alive
14 April 17 41/3000 CD 30 19 mixed alive
15 April 28 35/1840 CD 14 10 mixed alive
CD, cesarean delivery; VD, vaginal delivery; aindex case; b 2011; cunavailable information.
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Figure 2. The epidemic strain demonstrated continuous
transmission throughout the outbreak period. Three in-
fants were found to intermittently carry ESBL-E.coli.
This was assumed as a persistent colonization because
clearance followed by the reacquisition of the same
strain was thought to be unlikely to have occurred.
Contact precautions were implemented when screen-
ing samples tested positive for ceftazidime resistant or-
ganisms. The decision was also made to restrict the
admission of new patients. However, a third small clus-
ter of colonization cases involving two new patients oc-
curred one month after the last colonization case was
detected. Only one colonized infant was staying in the
NICU through this interval of time (no.5, Figure 2). This
infant was also the last colonized patient to be discharged
on June 16.
Based upon the weekly prevalence, the epidemic curve
showed three peaks with the outbreak reaching the high
number of colonization cases when the NICU was near
to the maximum of its bed capacity (Figure 1).
Detection of the epidemic E. coli strain was not per-
formed on the staff members or the environment.
The univariate analysis identified only a lower birth
weight as a risk factor associated with the acquisition of
ESBL-E. coli (cases vs. controls, 1,963 vs. 2,522 g, P = 0.02).
In contrast, transfer from another hospital, device use,
treatment with ampicillin-sulbactam and gentamicin
proved not to be risk factors. There were no statistically
significant differences in the length of stay betweencases and controls (median 14 vs.10, range 1–78 vs. 3–
155 days, P = 0.41).
At least two rectal swabs were cultured from 13 out of
the 15 infants colonized by ESBL-E.coli. The ESBL-E.coli
isolates were susceptible to carbapenems, gentamicin and
colistin. They were resistant to amoxicillin-clavulanate,
cefotaxime, ceftazidime, ceftriaxone, cefepime, ciprofloxa-
cin and levofloxacin. ESBL-E. coli was attributed with
phylogenetic group B2.
PCRs for blaCTX-M and aac(6’)-Ib-cr genes were posi-
tive. Sequencing identified the presence of blaCTX-M-15.
Resistances proved to be located on conjugative plas-
mids carrying FII and FIA replicons, able to transfer the
whole pattern of resistance to the recipient E. coli strain.
All isolates were analyzed by rep-PCR, showing a >95%
similarity. MLST analysis attributed isolates to ST131.
Infection control interventions
ESBL-E. coli colonized infants were placed under contact
precautions. Cohort care was implemented by desig-
nated healthcare workers (HCWs), but colonized infants
were not physically segregated after consideration of
facility design and ward staffing issues. The decision to
avoid overcrowding was also made on March 27 by
restricting the admission of new patients to the ward
(Figure 1). Thorough sanitization of surfaces, equipment
and caring devices was carried out. All NICU nursing
and medical personnel were informed of the outbreak
and training sessions on infection control practices and
modes of transmission of ESBL-E. coli were arranged.
Figure 2 Pattern of transmission of ESBL-Escherichia coli among the colonized infants in NICU during the outbreak period.
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carbapenems for infants showing suspected late-onset
sepsis were implemented. No further patients meeting
the case definition were observed after June 2012.
Discussion
The global rise of MDR organisms is a serious public
health threat. The influx in NICUs of community-
associated MDR organisms is of special concern and
jeopardizes the effectiveness of prevention and control
of measures tailored on healthcare-associated organisms.
Sources and routes of entry, indeed, may be different
with a more significant role of community reservoirs,
such as mothers and HCWs. Strategies to prevent and
control these organisms should likely differ as well.
We report an outbreak of colonization in a NICU by
an ESBL-E.coli strain. A similar event has been infre-
quently reported. Indeed, a cluster of neonatal invasive
infections by CTX-M-15 producing E. coli, two of which
lethal, was detected in 2005 in Algeria [13]. One further
fatal case of neonatal meningitis due to a CTX-M-15
producing strain has been described in France in 2005
[14]. Two additional outbreaks have been reported in
2010 in Switzerland and Spain, respectively, caused by
TEM-52 and CTX-M-14 producing strains [4,5].
The ESBL-E.coli detected in our investigation proved
to belong to the international hyperepidemic ST131
phylogroup B2 clone [1]. Accordingly, it showed plasmid-
carried blaCTX-M-15 and aac(6’)-Ib-cr resistance determi-
nants. In recent years, plasmid mediated resistances to
β-lactam antibiotics and fluoroquinolones have becomeincreasingly prevalent in community-onset E. coli infec-
tions [1,2]. The epidemiology of ST131 in Italy is poorly
characterized and can be inferred only by a few limited
studies. Twenty-four percent out of 148 fluoroquinolone-
resistant E.coli from uncomplicated urinary tract infec-
tions in eight European countries were attributed to the
ST131 clone, with a proportion of 34.4% within the Italian
isolates [2]. Moreover, ST131 clone was found to be
prevalent among 64 ciprofloxacin-resistant extra-intestinal
isolates in Rome, Italy, in 2006 [15]. Though poorly repre-
sentative, these data suggest that ST131 is likely circulat-
ing in the community in our geographic area.
Within the NICU patients under investigation, no
cases of infection due to the outbreak E. coli strain oc-
curred in the study period. This proves that clinically
silent intestinal colonization may contribute to the per-
sistence and spread of MDR Gram negative pathogens
in NICU. Detection of these events may be delayed or
missed completely if no active surveillance is in place
and culture results from clinical specimens are the pri-
mary means of identifying patients carrying these organ-
isms [16]. Moreover, three subjects had intermittent
recovery of ESBL-E.coli, which can be associated with
carriage at concentrations below the detection limit for
rectal swab specimens. This has been previously docu-
mented in epidemiological studies conducted in healthcare
settings, supporting the need for multiple cultures prior to
discontinuation of contact precautions or, alternatively, the
advisability to label as continuously colonized a patient
following the first isolation [17]. Of interest, infants
discharged from NICU have been recently demonstrated
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enterobacteria and to represent a significant reservoir for
intra-household spread of ESBLs [18].
In our experience, attempts were no performed to de-
tect an environmental contamination or carriage by
HCWs. Indeed in many MDR Gram negative outbreaks,
the stools of colonized infants have proved to be the res-
ervoir for the continued dissemination of the outbreak
strains [19,20]. In addition, environmental screening is
rarely useful for MDR Enterobacteriaceae, as the sensi-
tivity is generally low and the risk of a given site, such a
surface or a medical equipment, acting as a reservoir is
unpredictable [21]. Because the pattern of acquisition
suggested a cross-transmission between infants rather
than a common point-source, priority was given to mea-
sures aimed at interrupting the transmission chain. On
the other hand, previous outbreaks have been traced to
contaminated breast milk [3], or perinatal exposure dur-
ing vaginal delivery [5], both events being unlikely in our
situation because the index case was born by caesarean
section and exclusively formula-fed. However, the med-
ical history of this infant suggests that the outbreak
ESBL-E. coli strain was more likely first acquired into
the NICU and then disseminated via cross-transmission.
According with previous reports, ESBL-E. coli colo-
nization was associated with lower birth weight. No fur-
ther risk factors were identified. It is likely that spread
by cross-transmission was occurring regardless of the
different prevalence of possible exposures at risk be-
tween cases and controls.
Conclusions
Our report highlights the need to strictly monitor the
spills in the NICU setting of MDR community-associates
strains. As β-lactam and fluoroquinolone resistant E. coli
strains are increasingly spreading in the community, this
event could become more frequent. In our case, invasive
infections did not develop in any of the 15 neonates. How-
ever, serious or fatal infections have been previously de-
scribed [3,4,9,10]. More information about the prevalence
of ESBL-E.coli in the community is needed to accurately
assess and manage this risk in NICU.
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